Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laurent Taillade

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Bulletin Du Cancer|September 13, 2007
[Angiogenesis and renal cell carcinoma]Bertrand Billemont, Jean-Baptiste Méric, Hassan Izzedine, et al.
Bulletin Du Cancer|February 21, 2004
[Adjuvant chemotherapy in non-small cell lung cancer]Laurent Taillade, Jean-Charles Soria, Fabrice André, et al.
Cancer|February 2, 2011
Pulmonary toxicity related to systemic treatment of nonsmall cell lung cancerAlice De Sanctis, Laurent Taillade, Stephane Vignot, et al.
Radiology|January 23, 2010
Noninvasive contrast-enhanced US quantitative assessment of tumor microcirculation in a murine model: effect of discontinuing anti-VEGF therapyAymeric Guibal, Laurent Taillade, Sébastien Mulé, et al.
Lung Cancer (Amsterdam, Netherlands)|December 22, 2011
Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancerBenjamin Besse, David Planchard, Anne-Sophie Veillard, et al.
ERJ Open Research|April 26, 2018
Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancerAdrien Costantini, Jennifer Corny, Vincent Fallet, et al.
Acta Oncologica (Stockholm, Sweden)|June 5, 2023
FOLFIRI in advanced platinum-resistant/refractory small-cell lung cancer: a retrospective studyCyril Roussel-Simonin, Paul Gougis, Donia Lassoued, et al.
European Journal of Cancer (Oxford, England : 1990)|January 15, 2018
Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory diseaseFrançois-Xavier Danlos, Anne-Laure Voisin, Valérie Dyevre, et al.
The European Respiratory Journal|September 29, 2018
Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trialGuy Meyer, Benjamin Besse, Hélène Doubre, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Bulletin Du Cancer|September 13, 2007
[Angiogenesis and renal cell carcinoma]Bertrand Billemont, Jean-Baptiste Méric, Hassan Izzedine, et al.
Bulletin Du Cancer|February 21, 2004
[Adjuvant chemotherapy in non-small cell lung cancer]Laurent Taillade, Jean-Charles Soria, Fabrice André, et al.
Cancer|February 2, 2011
Pulmonary toxicity related to systemic treatment of nonsmall cell lung cancerAlice De Sanctis, Laurent Taillade, Stephane Vignot, et al.
Radiology|January 23, 2010
Noninvasive contrast-enhanced US quantitative assessment of tumor microcirculation in a murine model: effect of discontinuing anti-VEGF therapyAymeric Guibal, Laurent Taillade, Sébastien Mulé, et al.
Lung Cancer (Amsterdam, Netherlands)|December 22, 2011
Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancerBenjamin Besse, David Planchard, Anne-Sophie Veillard, et al.
ERJ Open Research|April 26, 2018
Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancerAdrien Costantini, Jennifer Corny, Vincent Fallet, et al.
Acta Oncologica (Stockholm, Sweden)|June 5, 2023
FOLFIRI in advanced platinum-resistant/refractory small-cell lung cancer: a retrospective studyCyril Roussel-Simonin, Paul Gougis, Donia Lassoued, et al.
European Journal of Cancer (Oxford, England : 1990)|January 15, 2018
Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory diseaseFrançois-Xavier Danlos, Anne-Laure Voisin, Valérie Dyevre, et al.
The European Respiratory Journal|September 29, 2018
Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trialGuy Meyer, Benjamin Besse, Hélène Doubre, et al.
Pageof 1